Merck Begins Tender Offer To Buy Idenix For $24.50/Shr - Quick Facts

(RTTNews) - Merck (MRK), known as MSD outside the U.S. and Canada, is commencing today, through a subsidiary, a cash tender offer to buy all outstanding common shares of Idenix Pharmaceuticals, Inc. (IDIX). On June 09, 2014, Merck announced its intent to acquire Idenix.

Follwing the completion of the tender offer, Idenix stockholders will receive $24.50 cash for each common share of Idenix validly tendered and not validly withdrawn in the offer, without interest and less any required withholding taxes. After the purchase of shares in the tender offer, Idenix will become a wholly-owned unit of Merck.

Merck will file today with the U.S. Securities and Exchange Commission or SEC a tender offer statement on Schedule TO, which provides the terms of the tender offer.